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At the time of reception of this article (April 2, 2020), efforts to develop a specific
vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019
(COVID-19), had just begun trial phase 1, but full validation of this and other current
developments is likely to take many more months to reach completion. The ongoing
pandemic constitutes a major health burden of world proportions that is also having
a devastating impact on whole economies worldwide, the knock-on effects of which
could be catastrophic especially in poorer countries. Alternative measures to ameliorate
the impact and hamper or minimally slow down disease progression are urgently called
for. This review discusses past and currently evolving data on the etiological agent
of the current pandemic, SARS-CoV-2, and its host cell receptors with a view to
disclosing alternative drugs for palliative or therapeutic approaches. Firstly, SARS-CoV-2
exhibits marked tropism for cells that harbor the membrane-bound metalloprotease
angiotensin-converting enzyme 2 (ACE2) at their plasmalemma, predominantly in cells
lining the oral cavity, upper respiratory tract, and bronchoalveolar cells, making these
epithelial mucosae the most likely viral receptor cell targets and entry routes. Secondly,
the crystal structures of several coronavirus spike proteins in complex with their cell host
target receptors, and of SARS-Cov-2 in complex with an inhibitor, are now available at
atomic resolution through X-ray diffraction and cryo-electron microscopy studies. Thirdly,
viral entry of other viruses has been successfully blocked by inhibiting viral endogenous
proteases or clathrin/dynamin-dependent endocytosis, the same internalization pathway
followed by ACE2 and some viruses. Fourthly, the target cell-surface receptor molecules
and SARS-CoV-2 possess other putative sites for drugs potentially modulating receptor
activity or virus processing. A multi-pronged pharmacological approach attacking
more than one flank of the viral-receptor interactions is worth considering as a
front-line strategy.
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INTRODUCTION
Human coronaviruses (HCoVs) were discovered in 1965 in patients with the common flu and
coined B814, with the prefix “corona” subsequently added in reference to their relatively large
spikes (or spines) resembling a crown (Li, 2013). HCoVs belong to the family of Coronaviridae
enveloped viruses that harbor between 26 and 32 kilobases of single-stranded positive-sense RNA,
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the largest so far observed for an RNA virus (Li, 2013; Su
et al., 2016), enveloped in a sphere of 80–120 nm in diameter.
CoVs infect a wide spectrum of avian and mammalian species.
Seven human CoVs are currently known. Members of the
first group (HCoV-OC43, HCoV-293, HCoV-NL63, and HKU1-
CoV) circulate in humans and generally cause mild, self-limiting
respiratory diseases. HCoVs in the second group are more
pathogenic and share the tropism for epithelial cells containing
membrane bound proteases; they are the etiological agents
responsible for the severe acute respiratory syndrome (SARS-
CoV), Middle East respiratory syndrome (MERS-CoV), and
the ongoing outbreak of CoV disease (COVID-19) purportedly
originating in the city of Wuhan, Hubei province in China.
The etiological agent, SARS-CoV-2, is a beta-CoV that has been
isolated from human bronchoalveolar epithelium of infected
patients (Zhou P. et al., 2020). Full-genome sequencing of SARS-
CoV-2 showed that it has 79.5% sequence identity with SARS-
CoV and is 96% identical to the Chinese bat CoV, BatCoV
RaTG13 (Zhou P. et al., 2020).
CoVs are related zoonotically, sharing common phylogeny
and structural properties but showing differences in tropism,
host range, cell-surface receptors, mechanisms for entry into
cells, etiopathology, clinical presentation and epidemiological
characteristics. In humans, CoV infections predominantly
affect the respiratory and gastrointestinal tracts. The potential
emergence of a SARS-like cluster of a circulating bat CoV,
SHCO14-CoV, with experimentally demonstrated human cell
infective capacity and high pathogenicity, was already reported
in 2015 (Menachery et al., 2015). The authors warned of
the potential risk of SARS-CoV re-emergence. Analysis of
evolutionary, genetic, and pathogenic aspects of CoVs reiterated
the warning (Su et al., 2016): “considering the high frequency
of recombination of these viruses, with unpredictable changes
in virulence, and with multiple viral species hosted by different
animals that are likely to interact with each other, it is not
a matter of if, but of when, a new CoV will emerge and
cause a new outbreak of human disease.” The current, perhaps
inevitable outbreak of COVID-19 attests to the correctness of
these predictions.
INFECTION: VIRAL RECOGNITION AND
ENTRY INTO TARGET CELLS
Coronavirus possesses four main structural proteins
[nucleocapsid (N), spike (S), envelope (E), and membrane
(M)] and various non-structural proteins (nsp). The surface
spike S glycoprotein plays the key role in addressing and
infecting the cell containing target membrane-bound receptors.
Virion entry is a multi-step process involving attachment to
the cell surface, receptor engagement, protease processing and
membrane fusion. The SARS-CoV enters human epithelial cells
in vitro through the apical surface, and viruses replicated in
these cells are also released via the apical plasmalemma. This
correlates with the cellular distribution of its main molecular
target at the plasmalemma, the angiotensin-converting enzyme
2 (ACE2), which in well-differentiated epithelial cells is more
abundantly expressed at the apical surface than in the basolateral
membranes and is used by SARS-CoV to readily infect such
differentiated cells (Jia et al., 2005). Based on this evidence, and
the phylogenetic kindredness among CoVs, it was highly likely
that SARS-CoV-2 would also follow the same entry route, as
recently demonstrated (Zhou P. et al., 2020).
It has long been known that the viral spike S glycoprotein
is critical for host range and tropism (Supekar et al., 2004;
Li et al., 2005). The S protein is a trimer, consisting of
three S1–S2 subunit heterodimers. During viral infection, each
trimer is cleaved into its S1 and S2 subunits. The S1 N-
terminal domain contains the receptor binding domain (RBD),
which can bind a variety of targets including polypeptide
segments of proteolytic enzymes like ACE2 or carbohydrate
moieties like neuraminic acid or heparan sulfate. In mouse
hepatitis virus (MHV) beta-CoV the S1 N-term domain is
recognized by cell adhesion carcinoembryonic antigen-related
cell adhesion molecule 1 (CEACAM1) (Kubo et al., 1994).
Another zinc metalloprotease enzyme, aminopeptidase N (APN,
CD13), acts as a viral-recognition protein for human H229E-
CoV, transmissible gastroenteritis virus, porcine epidemic
diarrhea, and feline infectious peritonitis virus. The enzyme
dipeptidyl-peptidase 4 (DPP4), also known as a cluster of
differentiation 26 (CD26), is found at the apical surface of
unciliated bronchial epithelial cells and performs this function
for MERS-CoV, a member of the beta-CoV genus which
is not recognized by the ACE2 receptor, and which has a
remarkable evolutionary ability to adapt to species variations
in its DPP4 cell-surface target by modifying the S protein
surface charge (Letko et al., 2018). In addition to using DPP4,
MERS-CoV can infect human pulmonary epithelial cells through
highly specific but low affinity interactions with sialic acid
residues present in host cell-surface glycoproteins (Li W. et
al., 2017) using a different region of its spike protein S
(Park et al., 2019).
Regarding the putative participation of DPP4 in SARS-CoV-2
infection, the notion that ACE2 shows relatively low expression
levels in alveolar cells led Zhang and coworkers (Qi et al., 2020)
to explore the expression of other proteins that might act as
co-receptors of SARS-CoV-2. Using single-cell gene expression
matrices, DPP4 was found to have a similar expression pattern in
multiple cells and tissues together with ACE2 and the peptidases
ANPEP and ENPEP (Qi et al., 2020); however, no evidence was
found of DPP4 acting as a co-receptor of SARS-CoV-2.
Carbohydrate moieties are likely to receive increasing
attention because of their role in spike protein-cell receptor
interactions. In a recent mass spectrometry study of a
recombinant SARS-CoV-2 (Watanabe et al., 2020) the glycan
moiety of the S glycoprotein was dissected in great detail. Each
trimer of the S glycoprotein contains 66 N-linked glycosylation
sites, which may participate in viral protein folding and
stability, but also intervene in viral tropism. Furthermore, the
glycosylation sites are under selective pressure, as they shield
viral epitopes from being recognized and neutralized by host
antibodies, thus facilitating immune evasion by a camouflage
mechanism as observed with the HIV envelope glycoprotein (Sok
et al., 2016).
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To identify the putative receptor of SARS-CoV-2, sequence
and phylogenetic analyses of other CoVs were carried out
together with a molecular modeling exercise on the S protein of
the SARS-CoV-2 virus. The results of these in silico studies led Xu
et al. to formulate the hypothesis that ACE2 was the SARS-CoV-2
cell host receptor (Xu et al., 2020b). This contention was followed
soon after by the experimental demonstration that ACE2 was
indeed the cellular target of SARS-CoV-2 (Zhou P. et al., 2020).
Remarkably, the S protein of HNL63-CoV, an alpha-CoV, is
recognized by ACE2 (Li et al., 2005). It is apparent that CoVs
exhibit predominant binding tropisms toward membrane-bound
proteases, but such tropisms are by no means absolute.
Spike S protein-mediated binding of CoVs to the surface of
the host cells and fusion to the cell-surface membrane appears to
be a conserved, shared mechanism. It is hypothesized, however,
that the two mechanisms may have evolved separately (Li, 2016):
ancestral CoVs would have initially harbored a primordial spike
with S2 domains only, functionally inefficient because the virus
had to randomly diffuse to reach target cells. Membrane fusion
eventually occurred in a receptor-independent manner. The
spike would have subsequently evolved to acquire a galectin-
like S1 N-term domain through gene capture, thus enhancing
CoV efficiency in infecting cells. A third evolutionary stage
is purported to be the appearance of an S1 C-term domain
through gene duplication of the S1 N-term domain (Li, 2016).
A comprehensive review on the binding-proteolytic activation-
fusion mechanism of CoVs entry (Millet and Whittaker, 2015)
emphasizes that the proteolytic activation step is the critical one
for the fusion of S1 to occur, since it allows for controlled release
of the fusion peptide into the target plasmalemma.
It should be noted that although ACE2 appears to be the
main cell-host receptor employed by SARS-CoV-2 to invade
cells, other putative receptor molecules have recently been
proposed, such as the surface glycoprotein CD147, also known
as EMMPRIN or Basigin, a member of the immunoglobulin
superfamily, with peptide-9 (an antagonist of C147) inhibiting
SARS-CoV-2 binding to HEK293 cells (Wang K. et al., 2020).
TMPRSS2 is a transmembrane serine protease expressed in
several tissue. The gene coding for this enzyme, TMPRSS2, is
the most frequently altered gene in primary prostate cancer
(Stopsack et al., 2020). This bears relationship to COVID-19,
because TMPRSS2 expression is regulated by sex hormones,
and COVID-19 shows predominance in males (Grasselli et al.,
2020; Guan et al., 2020; Richardson et al., 2020). TMPRSS2
activation is exploited by a variety of corona and filo-viruses
and Ebola virus (Zhou et al., 2015), and some influenza and
parainfluenza viruses (Laporte and Naesens, 2017) to activate
the viral protein machinery involved in the fusion with the host
cell plasmalemma. TMPRSS2 proteolytically activates MERS-
CoV (Shirato et al., 2013) and SARS-CoV (Matsuyama et al.,
2010) in vivo and in vitro. Most recently an engineered cell
line, VeroE6/TMPRSS2 (VeroE6 cell line expressing TMPRSS2)
was shown to be highly susceptible to SARS-CoV-2 infection,
suggesting the important role of TMPRSS2 in SARS-CoV-2
infection and indicating its potential utility for isolating and
propagating this virus (Matsuyama et al., 2020). The common
mechanism of action of TMPRSS2 on CoVs is the activation or
priming of the spike S proteins at the viral S1/S2 cleavage site
(Shen et al., 2017; Hoffmann et al., 2020a). Similarly, TMPRSS2
is involved in the cleavage of the hemagglutinin surface protein in
the case of some influenza viruses (Laporte and Naesens, 2017).
ACE AND ACE2 AND THEIR YING-YANG




Endothelial ACE is a key metallopeptidase enzyme in the renin-
angiotensin-aldosterone system (RAAS), playing a crucial role in
the regulation of blood pressure and homeostasis of body fluids.
Human endothelial ACE catalyzes the removal of the carboxy-
terminal dipeptide from the decapeptide angiotensin I to produce
angiotensin II, the active vasoconstrictor form of the hormone.
Angiotensin II and aldosterone are the two key biologically active
hormones of the RAAS homeostatic system (Li X. C. et al., 2017;
Mirabito Colafella et al., 2019). ACE2 is also a metalloprotease,
initially described in a study searching for novel genes related
to heart failure, and found in membrane-associated and secreted
forms predominantly in endothelial cells of human heart, kidney,
and testis (Donoghue et al., 2000). Endothelial ACE and ACE2
share 42% identical amino acid residues in their catalytic domain,
suggesting a common ancestor (Donoghue et al., 2000).
Avian influenza H5N1 virus, phylogenetically unrelated to
the CoVs, appears to affect the RAAS system: infected patients
exhibit higher levels of angiotensin II in serum, a sign
which correlates with the severity and lethality of the disease.
Furthermore, parallel studies conducted in animal models
showed that disease severity correlates with the downregulation
of ACE2 in lung, which can be reversed, increasing animal
survival, by administration of recombinant human ACE2 (Zou
et al., 2014).
Early epidemiological observations indicated higher
morbidity and mortality among elderly Chinese COVID-19
patients with hypertension and diabetes (Wu et al., 2020; Zhou F.
et al., 2020). In a cohort of 416 Chinese patients with COVID-19
about 60% had hypertension and ∼20% had cardiac injury (Shi
et al., 2020). Patients with severe COVID-19 and diabetes or
hypertension as comorbidities were advised not be treated with
ACE inhibitors or angiotensin IIAT1 receptor inhibitors because
a potential upregulation of ACE2 would facilitate and worsen
SARS-CoV-2 infection (Fang et al., 2020; Wan et al., 2020).
According to a recent study, the lack of statistically validated
data precluded an unambiguous statement on whether ACE
inhibitors or ARBS improve or worsen the severity of COVID-19
patients (Iaccarino et al., 2020). However, a recent retrospective
study on a large cohort of 18,472 patients tested for COVID-19
finds no association between ACEI or ARB use and positivity
for the disease (Mehta et al., 2020). Several medical societies
worldwide have expressed a strong recommendation to maintain
ACEI and ARBmedication in SARS-CoV-2 infected patients (see
Tignanelli et al., 2020).
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In the case of diabetes among COVID-19 patients, most
of the studies find diabetes mellitus the second most frequent
comorbidity, especially among the more severe cases requiring
hospitalization (Fang et al., 2020; Huang et al., 2020; Zhang B. et
al., 2020; Zhou F. et al., 2020); about 20% of the severe COVID-
19 patients admitted to ICUs presented diabetes as comorbidity
(Zhou F. et al., 2020). This is not surprising, given the association
of the disease with infection and the susceptibility of diabetic
patients to worse outcomes (Pearson-Stuttard et al., 2016). In
fact diabetes type 2 is associated with a low grade chronic
inflammation related to or induced by excessive adipose tissue
in multiple organs of the economy (Iacobellis, 2020). According
to this author the transmembrane enzyme DPP4 plays a major
role in glucose and insulin metabolism, degrading incretins
such as glucagon like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide, thus contributing to reduced insulin
secretion and abnormal visceral adipose tissuemetabolism. DPP4
also plays a role in immune regulation by activating T cells,
and is purported to increase inflammation in diabetic patients
(Iacobellis, 2020) In the case of COVID-19, diabetes has been
suggested to modulate the host-viral interactions and contribute
to ineffective host immune responses (Muniyappa and Gubbi,
2020). In an experimental model of ARDS, which is associated
with high severity and mortality among COVID-19 patients, the
DPP4 inhibitor sitagliptin decreased histological signs of lung
injury by hindering the release of pro-inflammatory cytokines
IL-1β, TNFα, and IL-6 (Kawasaki et al., 2018). Being a chronic
inflammatory condition, diabetes is associated with multiple
pathologies including vasculopathies (Klok et al., 2020) which are
in turn closely related to the coagulopathies increasingly being
observed in COVID-19 (Arachchillage and Laffan, 2020; Hussain
et al., 2020; Klok et al., 2020; Mei and Hu, 2020; Shi et al., 2020;
Wu et al., 2020).
The progressively mounting evidence on the involvement
of inflammation and hyperreactivity of the immune system in
COVID-19 refocuses attention on the anti-inflammatory action
of the ACE2 arm in RAAS. The “dilemma,” as recently put by
AlGhatrif et al. (2020), of whether to follow expert opinions and
employ ACEIs/ARBs in cardiovascular patients or discontinue
their use in those affected by COVID-19 is still alive. A dichotomy
between the role of ACE2 expression in young (who are expected
to have higher levels of the enzyme) or older adults (with age-
dependent lower ACE2 levels and exacerbation of the angiotensin
II pro-inflammatory arm) in COVID-19 outcomes is beginning
to take shape (AlGhatrif et al., 2020; Bavishi et al., 2020). The
latter authors hypothesize that SARS-CoV-2 binding to ACE2
acutely exaggerates the pro-inflammatory background.
In the short run, the current COVID-19 pandemic is posing
challenges that require unprecedented speed to resolve, in many
instances with insufficient evidence, as seems to be the case
with hypertension, diabetes and other presumed co-morbidities
and their pharmacological management. In the long run, some
authors hypothesize that upon control of the current COVID-
19 pandemic the SARS-CoV-2 will reemerge in its present or in
mutated forms and become chronic (Patel and Verma, 2020).
If this turns out to be the case, a deeper understanding of the
RAAS system in relation to CoV infection will be important,
as will the need to establish appropriate protocols for patients
suffering cardiovascular diseases and diabetes, the most common
non-communicable epidemic diseases.
ACE2, THE MAIN SARS-CoV-2 HOST CELL
RECEPTOR
Non-endothelial cells in heart and testis and tubular epithelium
of the kidney (Donoghue et al., 2000). Subsequent work screened
and found its expression in oral and nasal mucosae and
pulmonary alveolar and gastrointestinal epithelia, suggesting
possible routes of viral entry (Hamming et al., 2004; Xu H.
et al., 2020). An RNA-seq profiling study designed to explore the
putative presence of ACE2 in the epithelial mucosa of the human
oral cavity found highest expression in the tongue in comparison
to the gingival or the rest of the buccal mucosa (Xu H. et al.,
2020).
Pulmonary alveoli are lined by two types of epithelial cells
or pneumocytes: type 1 pneumocytes (AT1) are non-replicating,
large and relatively flat cells whose main function is to regulate
the O2-Co2 exchange. The smaller AT2 cells are involved in the
production and secretion of surfactant and a subpopulation of
these can re-differentiate into AT1 and other cell types upon
alveolar damage. SARS-CoV primarily targets ACE2 in ciliated
bronchoalveolar epithelial cells and AT2 cells (Li et al., 2003;
Qian et al., 2013) whereas MERS virus preferentially attacks AT2
cells (Rockx et al., 2020). The massive attack of AT2 cells by
SARS-CoV-2may significantly reduce their capacity to synthesize
surfactant, a factor that combined with the lower surfactant-
producing capacity in the elderly, may partly explain the severity
of the pulmonary complications in older patients (Grasselli et al.,
2020; Zhou F. et al., 2020). A recent immunocytochemical study
has further narrowed down the focus and localized expression of
ACE2 in the motile cilia of the respiratory tract epithelia, and
demonstrated that factors such as patient demography, clinical
presentation, and co-morbidities modify such expression (Lee
et al., 2020). One such co-morbidity is smoking, which reduced
mucociliary clearance by affecting the morphology of airway
epithelial cilia (Leopold et al., 2009).
A recent graph-based bioinformatic data analysis
corroborated that the highest, though not exclusive, expression
of ACE2 was in a very small proportion (0.64%) of all human
pulmonary cells. Of these, the vast majority (80%) corresponded
to AT2 cells (Zhao et al., 2020). In a recent study of COVID-19
in an animal (macaque) model system, both AT1 and AT2
pneumocytes, but predominantly AT2, were infected as well
as ciliated epithelial cells of nasal, bronchial, and bronchiolar
mucosae with severity increasing from MERS to SARS to
SARS-CoV-2 (Rockx et al., 2020). Interestingly, several other
ACE2-related genes that facilitate viral reproduction and
transmission are also highly expressed in the AT2 cells (Zhao
et al., 2020). Using a novel functional viromics approach,
the receptor binding domain of lineage B (beta)-CoVs can
be divided into functionally distinct clades. ACE2 was found
to be the entry receptor specific for clade 1 of such lineage.
When tested with this new assay, SARC-CoV-2 incorporated
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into cells expressing ACE2, but not into other cell-surface
receptors. Furthermore, several viruses exhibit compatibility
with a still unknown receptor in human cells (Letko et al.,
2020). ACE2 is developmentally regulated in mouse pulmonary
epithelium (Wiener et al., 2007). The lack of manifest clinical
symptomatology and/or severe forms of COVID-19 in children
and adolescents below the age of 15 mentioned above could be
related to the presence of an immature form of ACE2 in this
population, or lower expression levels of the enzyme, as recently
documented in a study of 305 individuals aged 4–60 showing a
clearly lower ACE2 gene expression in children <10 years old
(Bunyavanich et al., 2020).
Not all ACE2 isoenzymes were born equal. Coding variants
in different populations have recently been noted, and such
variability may account for binding affinities. ACE2-K26R is
more abundant in Ashkenazi Jews; this isoform has a lower
electrostatic attraction for SARS-CoV-2. In contrast, the virus
binds more to missense variants ACE-I468V, R219C, K341R,
D206G, and G211R (in increasing order), corresponding to
frequencies observed in East Asian, South Asian, African
and African American, European, European and South Asian
populations, respectively. The latter isoforms exhibit higher
electrostatic attraction, dominated by van der Waals forces (Ali
et al., 2020).
STRUCTURES OF CoV SURFACE SPIKE
PROTEIN S AND HOST CELL RECEPTOR,
ACE2
Development of drugs to tackle the current pandemic are
urgently needed, and knowledge of the structure of the virus, the
host cell receptor, and of the complex between the two are key to
guide drug design and repurpose existing drugs. During the last
few weeks there has been an explosion of high-resolution X-ray
crystallographic and cryo-electronmicroscopy (cryo-EM) studies
on the structure of the SARS-CoV-2 alone or in complex with
ACE2. This would have been impossible to accomplish in such
a short period were it not for the pioneer X-ray crystallography
work started more than 15 years ago on the structure of SARS-
CoV and MERS-CoV (Supekar et al., 2004; Li et al., 2005).
The group of McLellan has recently obtained the pre-fusion
structure of the SARS-CoV-2 S protein at 3.5 Å resolution
(Figure 1) and tested the putative binding of monoclonal
antibodies against the RBD of SARS-CoV, without finding any
apparent antibody cross-reactivity to SARS-CoV-2 (Wrapp et al.,
2020). The structure is quite similar to that of the S protein
from the human beta-CoV HKU1-CoV also obtained by cryo-
EM (Kirchdoerfer et al., 2016). Another recent cryo-EM study
has resolved the structure of the full-length human ACE2 with
or without the RBD of the S1 spike protein of SARS-CoV-2,
in the presence of a neutral amino acid transporter, B◦AT1,
which awards stability to the crystal structure, at a resolution
of 2.9 Å (3.5 Å at the RBD) (Yan et al., 2020). This is the most
detailed structure of ACE2 to date (Figure 2). Yet another cryo-
EM contribution has recently determined the structure of the
SARS-Cov-2 spike glycoprotein trimer and shown that it carries
a furin cleavage site between the S1 and S2 subunits, a peculiarity
of SARS-CoV and other CoVs (Wells, 2020). The S protein of
SARS-CoV-2 contains 4 redundant Pro-Arg-Arg-Ala amino acid
motifs which are not present in SARS-CoV. The proprotein
convertase furin fulfills the function of detaching these motifs
to enable the activation of the spike S protein and entry into
the host cell (Shang et al., 2020). The existence of the furin
mechanism overcomes the “default” state (mostly in the “down”
conformation) of the SARS-CoV-2 spike RBD, which is inefficient
for host cell binding.
One viral RBD is recognized by one extracellular peptidase
domain of ACE2, in a single molecule-to-molecule fashion
(Figure 2), in a manner akin to the recognition of SARS-CoV S1
protein by ACE2 (Li et al., 2005; Song et al., 2018; Hoffmann et al.,
2020a; Wells, 2020; Yan et al., 2020).
The affinity of ACE2 for the SARS-CoV-2 S1 spike protein
RBD has recently been reported to be similar (Correa Giron et al.,
2020; Wells, 2020) or 10–20 times higher than that of SARS-
CoV (Wrapp et al., 2020). In silico modeling of the SARS-CoV-2
protease involved in virion entry into cells has disclosed a high
degree of flexibility of the protein, which not only involves the site
where a known inhibitor binds, but also exposes other putative
sites where enzyme blockers could bind (Wells, 2020). Another
molecular dynamics study comparing the differences between
SARS-CoV and SARS-CoV-2 modes of binding to ACE2 suggests
that the RBD of the former virus has a stronger interaction with
the complementary ACE2 site (Chen Y. et al., 2020).
All in all, the structural information that has become available
in the last few years -and weeks- provides a still fragmentary but
comprehensive picture of the virus-cell receptor complexes at
atomic resolution with obvious implications for future structure-
based drug and vaccine design. At the time of resubmitting
this review (May 22, 2020) several vaccine candidates are being
developed at an unprecedented pace using various strategies
analyzed in Corey et al. (2020).
CLINICAL EPIDEMIOLOGY AND RISK
FACTORS FOR COVID-19
Lower respiratory tract infection with fever, dry cough, and
dyspnea are the most common, usually associated, presentations
of COVID-19 (Huang et al., 2020), and of these dyspnea appears
to be the most frequent predictor of the severe forms of the
disease and ICU admission (Jain and Yuan, 2020). The majority
of COVID-19 patients admitted to ICUs have been diagnosed and
treated as severe cases of pneumonia (Arentz et al., 2020; Chen
L. et al., 2020; Jain and Yuan, 2020; Wang D. et al., 2020; Zhou
F. et al., 2020). Initial reports pointed to several comorbidities
that constituted risk factors associated with severe forms of the
disease; these included hypertension, diabetes, cardiovascular
disease, older age, smoking, and chronic obstructive pulmonary
disease (Wu and McGoogan, 2020). Asthma does not appear to
be among the risk factors, as reported in the same study on a
large cohort of 72,314 patients, of which 44,672 were confirmed
COVID-19 cases (Wu and McGoogan, 2020). Other studies
pointed to a peculiar age distribution, which unlike other viral
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FIGURE 1 | Side (left) and top (middle) views of the SARS-CoV-2S protein prefusion structure with a single RBD in the “up” conformation obtained by cryo-EM. The
two RBD down protomers are shown in either white or gray surface rendering; the RBD “up” protomer is shown in green ribbon rendering. From the cryo-EM study at
3.5 Å resolution of Wrapp et al. (2020) (PDB 6VSB), used with permission from Science AAAS.
FIGURE 2 | Interactions between the receptor-binding domain (RBD) of SARS-CoV-2 and its cell-surface receptor molecule, the enzyme ACE2. The latter (light
blue-ribbon rendering) engages essentially a single linear motif, the α1-helix, to recognize the corresponding viral RBM (golden rendering), with contributions from the
α2-helix, as can be appreciated in the inset. From the cryo-EM study at 2.9 Å resolution of the SARS-CoV-2 RBD in complex with ACE2 in the presence of the neutral
amino acid transporter, B◦AT1 (PDB 6VW1) (Yan et al., 2020), held under Creative Commons license. The contact area between the a loosely packed binding motif in
the RBD and the two long helices of ACE2 is ∼1,700 Å2 (De Sancho et al., 2020).
diseases, largely spares children and adolescents below the age of
15 from the clinically manifest forms (del Rio and Malani, 2020;
Li Q. et al., 2020; Wu and McGoogan, 2020; Young et al., 2020),
accounting for <2% of the total cases of COVID-19 (Wu and
McGoogan, 2020). New statistics indicate that children<18 years
old represent<1.7% of all COVID-19 cases in the USA, 1% in the
Netherlands and 2% in the UK (Viner andWhittaker, 2020). The
authors discuss whether these figures “reflect lower susceptibility
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of children versus adults, or similar infection rates but much higher
proportions with asymptomatic disease.” However, as the number
of COVID-19 cases grow, so does the number of children affected
with a severe form of the disease. Most of these children have
been diagnosed with a multisystem inflammatory syndrome, in
some cases leading to shock (Viner and Whittaker, 2020), a
condition that has been interpreted as a delayed response to the
viral infection. This presentation of the disease bares similarity
to the Kawasaki disease, as recognized in an initial report from
Italy referring to the COVID-19 affected children as presenting
a Kawasaki-like disease (Verdoni et al., 2020). Kawasaki disease
is a rare, acute and usually self-limiting vasculitis of the medium
caliber vessels, which almost exclusively affects children (Viner
and Whittaker, 2020). Half of the children in the Italian study
required resuscitation (Verdoni et al., 2020); without treatment
up to 25% of cases can present coronary artery aneurisms
(Harahsheh et al., 2020), attesting to the severity of the syndrome.
The disease has been termed pediatric inflammatory multisystem
syndrome temporally associated with COVID-19 (PIMS-TS).
The initial notion that severe forms of COVID-19 are associated
only with adults, particularly elderly adults, potentially evolving
to fatal outcomes, is therefore changing; children share this severe
prognosis in a minority of cases.
PERSPECTIVES AND POSSIBLE AVENUES
FOR DRUG REPURPOSING AND
DEVELOPMENT
While much of what we need to know about the viral
spread, contagiousness, clinical evolution, prognosis, impact of
control measures for disease mitigation and other variables
of the COVID-19 disease remains terra incognita, critical
examination of the literature data shows that the considerable
progress accomplished in some basic aspects of other CoVs
like SARS-CoV or MERS, and more recently on SARS-CoV-
2 and host receptor(s) offers hints at possible developments
aimed at ameliorating disease progression and hopefully helping
therapeutic approaches tomaterialize. More thorough analyses of
physicochemical properties of anti-CoV drugs can be found e.g.,
in Liu et al. (2020).
Precise Specification of Viral Cellular
Targets Through Single-Cell Profiling and
Other Novel Techniques
The organ and tissue distribution of viral receptors, as well as
their expression levels, appear to be directly related to the choice
of cellular targets and infection routes adopted by the viruses.
An ACE2 RNA expression profile of normal human pulmonary
tissue showed that ACE2 is highly expressed in AT2 human
pulmonary cells, but that these constitute only a small percentage
(0.64%) of the bronchoalveolar epithelial lining (Zhao et al.,
2020). High expression is also found in the tongue (Xu H. et al.,
2020); however, the oral cavity, with a reported surface area of
215 cm2 (Collins and Dawes, 1987), represents only a minute
surface fraction compared to the upper respiratory tract and the
total pulmonary alveolar area (118 ± 22 m2 and 91 ± 18 m2 in
male and female individuals; Colebatch and Ng, 1992). The total
areas of the mucosae appear to be the only quantitative variable
available; we ignore receptor absolute numbers in each mucosa,
their density, and binding affinities required to assign the relative
probabilities of viral entry through each mucosa.
The technologies for conducting next-generation RNA
sequencing at the single-cell level (scRNA-seq) are currently
a reality. Such developments make it possible to undertake
transcriptome-wide analysis of differential gene expression
and differential splicing of mRNAs, and establish the tissue
distribution of molecular constituents in individual cells
(spatial transcriptomics, “spacialomics”) with unprecedented
discriminative power that surpasses conventional antibody-
based immunocytochemistry (for a review see Stark et al.,
2019). Another promising technique of recent implementation
is “TooManyCells,” a suite of graph-based algorithms that can be
applied to partition RNA-seq data to resolve and visualize clusters
of cells and establish their relationships in an unbiased manner
(Schwartz et al., 2020). With this technique only relatively
rare sets of cells, representing a mere 0.5% of the population,
could be resolved. Through these approaches, host-cell selectivity
of viral receptors could be narrowed down to the level of
cell populations, and subpopulations within a tissue or organ
with great precision, with inherent prophylactic and therapeutic
implications. Differences in the expression of ACE2 missense
mutants in different ethnicities were reported (Ali et al., 2020).
Such heterogeneity could also be reflected at the tissue and
cell levels in a given individual, explaining the variabilities in
risk, susceptibility and vulnerability of certain organs to become
targets of the disease. Data collected from more than 4 million
human cells by a large consortium of scientists in the Human
Cell Atlas project has recently shown through RNA-seq analysis
that SARS-CoV-2 can infect more cell types than previously
known (Muus et al., 2020). It also made apparent the occurrence
of cells co-expressing both ACE2 and the accessory proteases
that identify specific subsets of respiratory epithelial cells as
putative targets of viral infection in the nasal passages, airways,
and alveoli.
A recent immunocytochemical study has further narrowed
down the focus and localized expression of ACE2 in the motile
cilia of the respiratory tract epithelia, and demonstrated that
factors such as patient demography, clinical presentation, co-
morbidities modify such expression (Lee et al., 2020).
Exploiting Our Current Knowledge of
SARS-CoV-2 and Other CoVs to Inhibit
Virus Binding to Receptors
ACE2-RBD Inhibitors
Work on the structures of the S spike protein of CoVs and
ACE2 and their complexes has produced important information
and ideas not only on the relevant epitopes for vaccine design
(Li et al., 2003; Supekar et al., 2004; Imai et al., 2005; Struck
et al., 2012; Song et al., 2018) but also for interventions ranging
from application of recombinant ACE2 as protection against
severe acute lung failure (Imai et al., 2005) to the use of
ACE2 inhibitors in CoV diseases (Imai et al., 2005; Struck
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et al., 2012; Li, 2013; Song et al., 2018). A number of ACE2
peptide inhibitors with nanomolar affinity and a non-peptide
blocker with sub-nanomolar affinity, MLN-4760, have been
tested on the soluble form of ACE2 (Warner et al., 2004).
Current studies addressed at testing inhibitors of viral infection
in vitro have reported promising results with cepharanthine,
selamectin, and mefloquine hydrochloride, three drugs that
appear to hinder cytopathic effects of the GX_P2V virus, which
is 92% homologous to SARS-CoV-2 (Fan et al., 2020); no clinical
studies have been reported.
The TMPRSS2 Protease
The membrane-bound protease TMPRSS2 presumably serves
the role of co-receptor for SARS-CoV-2 engagement with ACE2
(Matsuyama et al., 2020). It has been shown to be blocked by
camostat mesylate (Hoffmann et al., 2020a), a serine protease
inhibitor previously found to inhibit Ebola and SARS-CoV
entry (Zhou et al., 2015). The drug has been clinically proven
in oncological therapy and treatment of pancreatitis in Japan
(Kawase et al., 2012) and shown efficacy in vitro in combination
with cathepsin inhibitors in SARS-CoV infected human HeLa
cells expressing ACE2 and TMPRSS2. A possible line of action
in drug development is to use this type of compounds as a
template on which to optimize the design of more selective
and/or more effective active-site or allosteric site inhibitor drugs.
Nafamostat mesylate, another serine protease inhibitor that has
been used in Japan for more than 30 years for pancreatitis
and as an anticoagulant of perfused blood known to inhibit
TMPRSS2-mediated host-cell entry of MERS-CoV (Figure 3)
and presumptively of SARS-CoV-2 (Iwata-Yoshikawa et al.,
2019), has been recently employed alone, to block activation
of SARS-CoV-2 (Hoffmann et al., 2020b), or in combination
with heparin as an anti-enhanced fibrinolysis therapy for the
coagulopathies observed in severe cases of COVID-19 (Asakura
and Ogawa, 2020).
Inhibiting Virus Endocytic Internalization
and Intracellular Trafficking
To enter the cells, many viruses appropriate canonical endocytic
pathways used by cells under physiological conditions. One
of the earliest mechanisms of CoV endocytosis studied is
that of mouse hepatitis virus MHV-4; infection occurs via
endocytic and non-endocytic mechanisms (Nash and Buchmeier,
1997). Viral endocytic internalization operates via a clathrin-
dependent, caveolin- and EPS-15-independent mechanism (Pu
and Zhang, 2008). Drugs that inhibit the clathrin- and dynamin-
dependent endocytic pathway impede dengue virus infection of
mononuclear phagocytic cells (Carro et al., 2018). Temporary
inhibition of endocytosis with the anti-emetic/anti-psychotropic
drug prochlorperazine is deemed to be potentially safe in humans
(Chew et al., 2020). The SARS-CoV S protein is digested by
cathepsin L or B in the lumen of the endocytic compartment,
and on this basis the use of protease inhibitors has been explored
as potential broad-spectrum anti-CoV agents, including SARS-
CoV (Zhou et al., 2015). Expression of exogenous cathepsin L
significantly enhances SARS-CoV but not HNL63-CoV infection
via ACE2 (Huang et al., 2006). This exemplifies how two CoVs
that target a common receptor molecule infect the cells using
different mechanisms.
Experimental demonstration that SARS-CoV-2 enters HEK-
293 cells engineered to express human ACE2 in vitro (HEK-
293/hACE2) via an endocytic mechanism has become available
(Ou et al., 2020). Cathepsin plays a critical role in this process.
Viral endocytic mechanisms have gained recent attention
partly because there are drugs available to inhibit specific
internalization pathways. Endosomal maturation is accompanied
by a drop in the endosomal pH. The relatively simple organic
anti-malaria compounds chloroquine and hydroxychloroquine
(see Figure 3 and recent review in Touret and de Lamballerie,
2020), used since before mid-twentieth century, is known
to moderately raise the pH of endosomes and/or lysosomes,
hindering viral fusion, uncoating and further processing in the
endosomal lumen and lysosome.
Additional mechanisms beyond inhibition of endocytic
internalization are suggested by biotechnological studies on
nanoparticle uptake by macrophages (Hu et al., 2020) The
possible prophylactic or therapeutic effects of chloroquine and its
derivative hydroxychloroquine, also employed for autoimmune
diseases (Colson et al., 2020), lupus and rheumatoid arthritis,
is currently being subjected to clinical trials for COVID-19 in
China and France (Devaux et al., 2020); critically validated results
are still being awaited within the context of the SOLIDARITY
program launched by the World Health Organization (see
Table 1). Both drugs have a rather narrow margin between
therapeutic and toxic effects, some of them lethal (Touret and
de Lamballerie, 2020). It is contended that chloroquine and
derivatives not only affect the endocytic mechanisms of viral
entry but may also interfere with the SARS-CoV-2 replication
cycle (Devaux et al., 2020). A recent retrospective multi-center
study on a large cohort of randomly chosen 1,438 patients
treated with hydroxychloroquine alone or in combination with
the antibiotic azithromycin in 25 hospitals (representing 88.2%
of all hospitalized COVID-19 patients in New York) showed
no significantly lower mortality but more frequent ventricular
arrhythmias and cardiac arrest in patients medicated with the
drug combination (Rosenberg et al., 2020) (Table 1).
There is an additional component in the virion infection
process: the cytoskeleton. Entry of the porcine hemagglutinating
encephalomyelitis virus, a member of the CoV family, into N2
cells is facilitated by rearrangement of the cytoskeleton via the
α5β1-FAK/cofilin/Rac1/cell division cycle Cdc42 pathway (Lv
et al., 2019). Unfortunately, the ubiquity of the cytoskeleton
precludes therapeutic interventions.
ACE and ACE2 in the Context of RAAS:
New Strategic Approaches
In addition to contemplating ACE2 as the molecule targeted by
SARS-CoV-2, it is important to envisage this enzyme as a key
target of therapeutic interventions based on its role in pulmonary
inflammatory pathologies. Indeed, the ACE2/Ang (1–7)/Mas
receptor pathway is a potential therapeutic target worth exploring
for ameliorating allergic inflammation of the respiratory tract,
respiratory airway remodeling, and airway hyperresponsiveness.
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FIGURE 3 | Vital cycle of SARS-CoV-2 from host cell receptor binding to exocytic virion shedding.
Acute respiratory failure with bilateral infiltrates and hypoxemia,
without hydrostatic pulmonary edema, configures a potentially
severe nosological entity eventually leading to acute respiratory
distress syndrome, an inflammatory condition involving
increased vascular permeability and hypoxemic respiratory
failure (Bellani et al., 2016). The syndrome appears to be one of
the most common complications of COVID-19. The severity of
pneumonia and acute respiratory failure is positively correlated
with age-dependent disequilibria of the ACE/ACE2 ratio
(Schouten et al., 2016; Tan et al., 2018). Furthermore, reduced
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TABLE 1 | Some examples of current clinical trials with repurposed drugs.
Drug trial Outcome Observations References
Lopinavir/ritonavir No benefit was observed with lopinavir-ritonavir
treatment beyond standard care.
Patients (n = 199) with similar viral RNA load and
clinical status. Median of 13 days from onset of
disease to randomization
Cao et al., 2020
Lopinavir/ritonavir Pending secondary outcome analyses, the study
concludes suggesting substantial diminution of
overall mortality (19 vs. 25 in standard care group),
risk of respiratory failure (13% vs. 27%)
Contradicts conclusions of Cao et al. (2020).
Patients (n = n/a) in this trial underwent
randomization a median of 13 days after disease
onset. Initiating therapy earlier may be more
effective, since systemic hyperinflammation rather
than viral pathogenicity dominates later stages
Dalerba et al., 2020
Darunavir/cobicistat plus
hydroxychloroquine
A “post-exposure prophylaxis (PEP)” trial aimed at
treatment of COVID-19 cases with the HIV drug
combination darunavir/cobicistat plus
hydroxychloroquine treatment and
chemoprophylaxis of household contacts having
spent >15min with infected patients. Results
pending
To evaluate the efficacy of the “test and treat”
strategy of infected patients and prophylactic
chloroquine treatment to all contacts (Patients
recruited n = 1,000). Decentralized COVID-19
testing and starting chloroquine treatment
immediately in all who are found to be infected.
Control group receives no medication
Fundacio Lluita Contra la
SIDA in collaboration with
Department of Health,
Generalitat de Catalunya,




release U.S. National Library
of Medicine
(ClinicalTrials.gov)
Hydroxychloroquine No difference, but sampling may not have been
adequate
Patients (n = 150) with too late (28 day) viral
clearance and randomized too late in the course of
the disease
Tang et al., 2020
Chloroquine/
Hydroxychloroquine
Chloroquine or placebo in Asia, hydroxychloroquine
in Africa. Expected outcome: After 5 months follow
up determine clinical conditions of
prohylactic/therapeutic approach. Estimated
commencement: April 2020; end: April 2021
Participants (expected = 40,000) of a double-blind
randomized, placebo-controlled trial to be
conducted in healthcare settings or COVID-19
proven or suspected individuals
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Hydroxyhloroquine alone or in
combination with azytromycin
No significant lower mortality; more frequent cardiac
arrest in patients treated with the drug combination
Patients (n = 1,438) from 25 hospitals representing
88.2% of all hospitalized COVID-19 individuals in
New York
Rosenberg et al., 2020
Hydroxychloroquine A phase 2/3 trial to test kinetics of
hydroxychloroquine medication in a blind,
randomized fashion. Start date: April 17, 2020.
Completion due: July 1, 2020
Patients (n = 58) medicated with
hydroxychloroquine to test whether medication will
decrease the amount of virus (as measured by
PCR), 7 days after initiation of therapy compared to
control randomized patients receiving placebo





Either drug alone or in combination with a macrolide
increased the risk of de-novo ventricular arrhythmia.
Trial started 20 December, 2019 and ended April
14, 2020
Multi-center study including 96,032 COVID-19
hospitalized patients (671 hospitals in six continents)
medicated with chloroquine alone,
hydroxychloroquine alone, or either drug in
combination with a macrolide
Mehta et al., 2020
Lopinavir/ritonavir vs. umifenovir
vs. control
No difference for primary or secondary outcomes Patients (n = 86) in an open-label trial randomized
2:2:1 The primary endpoint set at time of negativity
of RT-PCR
Li Q. et al., 2020
Hydroxychloroquine Prospective clinical study in the prevention of
COVID-19 among healthcare personnel after high
exposure to SARS-CoV-2. Start date: April 3, 2020.
Estimated completion date: July 30, 2020
Participants (n = 336) non-randomized, parallel
assignment; 50% subjected to oral
hydroxychloroquine for a total of 7 weeks. Baylor
University Medical Center, Dallas, Texas
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Remdesivir Non-statistically significant tendency suggesting
less mortality rate in a subset cohort starting
medication within 10 days of symptom onset
Patients (n = 236) assigned to remdesivir or
placebo groups. Randomization according to type
of non-assisted/supported respiration. Many
patients received steroids
Wang et al., 2020
(Retracted by the journal
The Lancet)
Remdesivir Remdesivir-treated patients showed accelerated
(31%, median 11 days) recovery relative to placebo
group (median 15 days, p < 0.001). Results also
suggest survival benefit (mortality rate 8% vs. 11.6
in placebo group). Most beneficial for severe cases
requiring oxygen supply
Patients (n = 1,063) were hospitalized COVID-19
patients from 10 countries recruited by NIH National
Institute of Allergy and Infectious Diseases (NIAID)
for a randomized, controlled clinical trial named
Adaptive COVID-19 Treatment Trial (ACTT)
NIH press releases of April
29 and May 22, 2020 and
Beigel et al., 2020
(Continued)
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TABLE 1 | Continued
Drug trial Outcome Observations References
Remdesivir No differences were observed in the improvement of
severe COVID-19 patients who received remdesivir
for 5 or 10 days. 10% of the patient developed
acute respiratory failure
Hospitalized patients (n = 397) underwent a 5 or 10
day course randomized treatment. A phase 3 trial
named SIMPLE by commercial firm (Gilead
Sciences, Inc.). No placebo group. Study will be
extended to enroll 5,600 patients at 180 locations
Press release Gilead Sci.
Inc.
Tocilizumab To evaluate the drug tocilizumab, a monoclonal
antibody that blocks interleukin-6 receptor. Primary
outcome was for either need for mechanical
ventilation or death. Preliminary data indicate
“tocilizumab improves significantly clinical
outcomes”
Patients (n = 129) with moderate to severe
COVID-19. Open-label, randomized, multi-center,
controlled trial conducted in Paris hospitals to
evaluate efficacy and tolerance of various immune
modulators. No placebo group (50% patients




Paris, 27 April, 2020
Tocilizumab To establish proof-of-concept that the drug
tocilizumab, a monoclonal antibody that blocks
interleukin-6 receptor is effective in decreasing
clinical signs, symptoms, and laboratory evidence of
COVID-19 pneumonitis. Begins April4, 2020; ends
July, 2020
Patients (n = 50), hospitalized, non-critically ill with
COVID-19, showing clinical risk factor(s) for
decompensation, ICU utilization, or death. A second
group of patients without risk factor for
decompensation. Sponsor: Univ. of Chicago
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Tocilizumab A phase 2 trial on patients affected by severe
multifocal interstitial pneumonia correlated to
SARS-CoV2 infection. Start date: March 12, 2020.
Estimated completion: May, 2020
Patients (n = 38) to test the hypothesis that an
anti-IL-6 receptor drug calms the virus-induced
cytokine storm, blocking deterioration of lung
function or even promoting a rapid improvement of
clinical conditions
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Sarilumab Sarulimab, a human IgG1 monoclonal antibody that
binds specifically to both soluble and membrane
bound IL-6 receptor, did not improve conditions of
severe COVID-19 group of patients; the group did
not progress to phase 3. New enrollment will only
contemplate critically-ill patients
Patients (n = 457) underwent a phase 2/3
commercial-sponsored trial (Regeneron-Sanofi
U.S.). The monitoring committee recommended
continuing the trial of sarilumab (Kevzara) only with
the critically-ill group of patients, discontinuing it
with the severe group of patients
Press release of Regeneron
(Tarrytown, N.J.) and Sanofi
(Paris) on April 27, 2020
Sarulimab Phase 2/3 trial to evaluate therapeutic effect and
tolerance of Sarilumab. Commencement: March
2020; expected completion by March 2011
Patients (n = 239) from Paris Hospitals. Bayesian
open labeled randomized clinical trial in patients
with moderate, severe pneumonia or critical
pneumonia associated with COVID-19
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Ivermectin A pilot, proof-of-concept trial. Commencement
date: May 11, 2020. Completion date: June 30,
2020
Patients (n = 45) from University of Salta, Garrahan
Pediatric Hospital, Buenos Aires, Argentina. Based
on in-vitro studies indicating suppression of
SARS-CoV-2 replication, the trial will evaluate
clinical applicability of the drug in a randomized
study at early stages of COVID-19





A pilot, proof-of-concept trial to establish rate and
time of viral clearance in subjects receiving the
combination of three drugs. Commencement date:
May, 2020. Completion date: May 2022
Patients (n = 100) with COVID-19 will receive the
combination of nitazoxanide, ribavirin and ivermectin
vs. a control group without medication for a duration
of seven days in a randomized, sequential scheme
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Telmisartan The drug telmisartan will be assessed in a pilot
study due to commence on May 15, 2020 and with
an estimated conclusion in October 1, 2020
Patients (n = 400) from Hospital de Clínicas José de
San Martín, Faculty of Medicine, University of
Buenos Aires, will receive telmisartan twice daily in
an open-labeled, parallel assignment randomized
trial
U.S. National Library of
Medicine press release
(ClinicalTrials.gov)
Prazosin The α-blocker prazosin will be tested to evaluate
whether it reduces ICU admission rate or need of
assisted ventilation among COVID-19 severe
patients. If test proves successful, a follow-up is
planned with COVID-19 positive individuals who are
not yet hospitalized
COVID-19 patients (n = n/a) aged 45–85 at John
Hopkins Hospital, Baltimore, will receive gradually
increasing doses of the α-blocker prazosin
(Minipress) for 6 days and compared with a control
group of patients receiving “standard” treatment
Vogelstein et al., 2020
ACE2 activity has been observed in experimentally-induced
acute respiratory distress syndrome. Therapeutic intervention
with a protease-resistant form of angiotensin (1–7) improved
all symptoms, indicating the possible association of angiotensin
(1–7) deficiency with the syndrome (Wösten-van Asperen et al.,
2011).
As more is learned about the clinical aspects of COVID-
19, it is recognized that a subset of these patients, more
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often those suffering severe forms of the disease, develop
dysregulated systemic hyperinflammatory reactions also known
as macrophage activation syndrome, cytokine release syndrome
or “cytokine storm,” consisting in the over-production of
pro-inflammatorymediatormolecules, predominantly cytokines.
These include interleukin (IL)-6, IL-2R, IL-8, tumor necrosis
factor-α, and granulocyte-colony stimulating factor (2, 4–8)
(Moore and June, 2020; Zhang B. et al., 2020). The cytokine
release in response to the SARS-CoV infection had already
been observed with alveolar cells in culture infected with this
CoV (Qian et al., 2013). Among the possible strategies to
address this syndrome is to interfere with the “master player”
interleukin-6 (IL-6)/IL-6 receptor/gp130 axis (Uciechowski and
Dempke, 2020) employing e.g., IL-6 receptor inhibitors (Kang
et al., 2019). Corticosteroids are in general not recommended
(Sanders et al., 2020). Tocilizumab and sarilumab, monoclonal
antibodies targeting the IL-6 receptor, and siltuximab, a chimeric
antibody targeting IL-6, are currently being investigated for the
treatment of patients with COVID-19 and ARDS complications;
the potential of tocilizumab to curb the cytokine storm was
reported in a retrospective study of a small number of patients (n
= 21) in China with severe/critical COVID-19 who underwent
treatment with the anti-IL-6 monoclonal antibody tocilizumab.
Patients showed important reductions in morbidity and need
for mechanical ventilation (Xu et al., 2020a). The antibody has
now entered into various clinical trials (examples in Table 1;
additional clinical trials listed in Konig et al. (2020) and
Clinical.Trials.gov). The cost and potential adverse reactions may
restrict the use of this approach to patients in developed countries
according to Konig et al. (2020).
A recent retrospective meta-analysis of a large number of
patients with acute respiratory distress or pneumonia (n =
13,125 and n = 108,956, respectively) from all causes led to the
inference that those patients who were taking α-blockers had a
lower risk of requiring ventilation (by 35 and 16%, respectively)
and a reduced risk of requiring assisted ventilation and dying
(by 56 and 20%, respectively), compared to non-users of α-
blockers (Vogelstein et al., 2020). Based on this information
and previous knowledge that catecholamines enhance pro-
inflammatory reactions through a self-amplifying loop mediated
by α1-adrenergic receptors that increase the production and
release of IL-6 and other cytokines, and the amelioration of
these phenomena by pharmacological catecholamine blockade
in animal models (Staedtke et al., 2018), a clinical trial testing
prazosin, a post-synaptic α1-adrenergic receptor competitive
antagonist is underway (Table 1).
The SARS-CoV-2 and Its Endogenous
Proteases
Attacking the virus itself is another attractive possibility. Any of
the viral proteins and the mRNA are possible targets, especially
using drugs already developed for other viruses or modifications
thereof. Among such already existing drugs are the inhibitors of
the endogenous CoV proteases active downstream of infection
for the biosynthesis of polyproteins translated from the viral
RNA. This constitutes an important avenue of research since
these endogenous proteases are required for the processing
of two viral polyproteins, pp1a and pp1ab, into the 16 non-
structural proteins involved in the production of subgenomic
RNAs that encode, in turn, no less than the 4 structural
proteins of SARS-CoV-2 (Dai et al., 2020). MPRO, also termed
3CLPRO, is the key enzyme needed for the cleavage of the
two polyproteins in SARS-CoV. Forty unsymmetrical aromatic
disulfide compounds have been synthesized and tested in vitro
and found to be reversible competitive inhibitors of MPRO
activity, blocking viral replication. In silico docking was used to
validate the in vitro assays (Wang et al., 2017). In SARS-CoV-
2 an important endogenous protease is the papain-like protease
(PLPRO), whose atomic structure is still not known. Based on
available crystallographic data of the PLPRO from SARS-CoV
and MERS-CoV, a recent homology modeling study found that
the PLPRO of SARS-CoV-2 is 97% homologous to that from
a bat CoV, 80% to SARS-CoV and only 29% homologous to
MERS-CoV (Stoermer, 2020).
The recent availability of the co-crystal of MPRO from SARS-
CoV-2 with an α-ketoamide inhibitor (Zhang L. et al., 2020)
(Figure 4) and two structure-based design additional inhibitors,
11a and 11b (Dai et al., 2020) provides a structural basis on which
to validate the in silico calculations and develop new virion entry
blockers. A virtual screening of more than 3,000 compounds
FIGURE 4 | Substrate-binding cleft of MPRO, the endogenous protease in
SARS-CoV-2, with compound 13b, a peptidomimetic α-ketoamide inhibitor of
the viral enzyme. Fo-Fc density is shown for the inhibitor. Atom color
rendering: magenta, carbon (except in the pyridone ring, which is black), red,
oxygen; blue, nitrogen, and yellow, sulfur. Light-blue symbols S1, S2, S3, S4
indicate the canonical binding pockets for moieties P1, P2, P3, P4 (red
symbols) inhibitor. Red dashed lines represent H-bonds. Inset: Thiohemiketal
resulting from the nucleophilic attack of the catalytic Cys residue on the
α-carbon of the inhibitor in its Fo-Fc density (contoured at 3σ). From Zhang L.
et al. (2020), held under Creative Commons license.
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approved by the American Federal Drug Administration recently
focused on the MPRO of SARC-CoV-2 (Contini, 2020). Protease
inhibitors previously or currently used in HIV retroviral therapy,
like lopinavir, indinavir, and atazanavir were selected as potential
candidates applicable to COVID-19 (Contini, 2020;Wang, 2020).
The lopinavir +ritonavir combination has been used an HIV
protease inhibitor, but a randomized, controlled study of 199
confirmed COVID-19 patients reported no benefits of dual drug
administration, which was therefore interrupted (Cao et al.,
2020) (see Table 1). Ritonavir inhibits the metabolizing enzyme
cytochrome P450 3A, increasing the half-life of lopinavir. In
another study the same FDA database was explored using free
energy calculations, and dypyradamol was selected as the most
promising drug, which according to the authors is undergoing
clinical trials (Li Z. et al., 2020). Using the crystal structure
of the viral proteases as a template, repurposing database
screening combined with thermodynamics of ligand binding
have highlighted the drug carfilzomib, an approved anti-cancer
drug, as the best potential candidate to inhibit SARS-CoV-2
infection at the level of the proteasome, with a free energy of
binding of −13.8 kcal mol−1. Antibiotics like ervacycline or
streptomycin were also singled out (Wang, 2020). An important
feature of blocking this viral protease, unlike other actors in the
viral life cycle, is that no enzyme with such cleavage specificity
is found in humans, thus minimizing the potential toxicity of
inhibitors in therapeutic approaches to COVID-19.
In SARS-type CoVs, the non-structural protein 16 (nsp16)
methylates the 5’-end of virally encoded 28 mRNAs to mimic
cellular mRNAs, thus protecting the virus from host innate
immune restriction. The 1.8 Å structure of a ternary complex
of full-length nsp16 and nsp10 of SARS-CoV-2 in the presence
of cognate RNA substrate and a methyl donor, S-adenosyl
methionine, provide mechanistic information on viral mRNA
cap (Viswanathan et al., 2020).
A proteomic and translational in vitro analysis has explored
metabolic pathways followed -and altered- by SARS-CoV-2 when
infecting cells, including translation, glycolysis, splicing, and
nucleotide synthesis, identifying several small drugs inhibiting
viral replication in cells in a temporal-dependent manner
(Bojkova et al., 2020).
The diversity of candidate drugs resulting from “repurposing”
database analyses, in some cases stemming from the same
database, calls for alternative refining techniques. Deep
learning is increasingly gaining momentum in protein structure
prediction (Wardah et al., 2019; Senior et al., 2020; Singh,
2020). Deep learning strategies have also impacted on the field
of drug design (Dana et al., 2018). Such strategies constitute a
viable methodology which should be exploited to screen data
banks of small drugs docking on cell host and viral proteases,
SARS-CoV-2 surface proteins and other putative targets on the
basis of structural and thermodynamic parameters, find new
suitable small drug inhibitors, and explore combinations of two
or more drugs acting synergistically on different targets.
The SARS-CoV-2 RNA Polymerase
SARS-CoV-2 replicates its genome and transcribes its genes
using an RNA-dependent RNA polymerase (RdRp), also called
nsp12. The first-generation anti-HIV drugs aimed at the replicase
enzymatic machinery responsible for RNA replication are the
nucleotide analog drugs like remdesivir, a broad-spectrum
inhibitor of RdRp originally designed for the Ebola virus
and congeners, and whose effectiveness against COVID-19
is currently being investigated. Tested on a Rhesus macaque
model of COVID-19, when applied early in the course of
the experimentally-induced disease, the drug was effective in
preventing the progress of the illness but did not inhibit virus
shedding by the infected animals (Williamson et al., 2020). The
anti-hepatitis C antiviral drug ribavirin is another of the potential
drugs listed as candidates by the World Health Organization, but
26 out of 30 studies reviewed in a recent meta-analysis indicate
inconclusive results and liver and hematologic toxicity with this
drug in COVID-19 patients (Sanders et al., 2020).
Very recent cryo-EM studies have determined the structure of
RdRp. The first, produced by the group of Xu and coworkers in
Shanghai, solved the structure of the apo form of RdRp alone at
2.8 Å resolution, and in complex with a 50-base template-primer
RNA plus the viral inhibitor remdesivir, at 2.5 Å resolution (Yin
et al., 2020). From the structure of the complex these authors
concluded that remdesivir works by acting as an immediate
RNA chain terminator and suggested a rational template for
future drug design. A second study at the Max-Planck-Institute
for Biophysical Chemistry in Göttingen rendered the structures
of RdRp (nsp12) together with the non-structural proteins
nsp7 and nsp8 over two turns of the RNA template-product
duplex (Hillen et al., 2020). These authors indicated that the
work of Xe and coworkers contradicted biochemical evidence
showing that remdesivir causes delayed chain termination after
addition of more nucleotides. Aside from the differences in
interpretation, the two studies coincide in their core structural
findings, providing new insights into the mechanisms utilized by
antivirals such as remdesivir, and in the design of better inhibitors
of the viral RNA polymerase. A third study, also using cryo-EM
at 2.9 Å resolution, solved the structure of RdRp in complex with
cofactors nsp7 and nsp8, with inferences from parallel modeling
studies on the possible use of favipiravir, given its similarity to
remdesivir (Beigel et al., 2020; Gao et al., 2020) (see Table 1 for
clinical trial). The therapeutic possibilities are thus not limited to
using remdesivir only, but extend the RNA polymerase inhibitor
strategy to a whole family of compounds including ribavirin,
remdesivir, sofosbuvir, galidesivir, and tenofovir as well as other
compounds like the guanosine derivative IDX-184, setrobuvir,
and YAK, which have FDA approval in the U.S.A. (Elfiky, 2020).
Lipid Metabolism in CoV-Infected Cells
Plus-strand RNA virus replication, as with CoVs, sequesters the
lipid metabolic machinery in the infected cell, hijacking the
enzymes normally involved in lipid synthesis and processing.
Structurally this results in the formation of double-membrane
vesicles and other abnormal membrane structures generically
referred to as replicative organelles. These are the platforms for
virion replication and transcription and virion morphogenesis.
An inhibitor of the cytosolic phospholipase A2α, pyrrolidine-
2, was found to reduce the formation of double-membrane
vesicles in cells infected with the related human H229E CoV,
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impairing virion replication (Müller et al., 2018). The drug also
diminished the formation of lyso-phospholipids, the products of
phospholipase A2α enzymatic activity that are essential for CoV
replication. It would be worth exploring the lipidomics of SARS-
CoV-2 to investigate whether the virus possesses any singularity
in terms of composition which can be exploited in its control.
A recent retrospective analysis of 861 patients with clinically
classified mild, moderate, severe or critical (the latter with
respiratory failure, shock or organ failure) COVID-19 analyzed
the possible association with plasma cholesterol and HDL on
morbidity and prognosis (Wei et al., 2020). The levels of total
cholesterol and HDL were found to be inversely correlated
with the severity of the disease, and severely ill patients with
high HDL had a better prognosis. Survivors also had higher
cholesterol and HDL levels. Furthermore, pretreatment with ITX
5061, a potent antagonist of SR-B1 that increases HDL levels,
competitively inhibited infection of HEX-293T by the virus
(Wei et al., 2020), thus providing another avenue of possible
prophylactic intervention. Interestingly, these authors analyzed
the sequences of SARS-CoV-proteins and found the presence of
6 cholesterol recognition motifs like the ones we have described
in membrane proteins (Fantini and Barrantes, 2013), including
the adjacent mirror CARC-CRAC motif (Fantini et al., 2016).
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